Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Jeffrey R. Infante | Researchclopedia

Back to researchers

Jeffrey R. Infante

565

Works

30,944

Citations

78

h-index

250

i10-index

Research Topics

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies

Affiliations

Rutgers, The State University of New Jersey2017–2017

University of North Carolina at Chapel Hill2010–2010

Tufts University2014–2014

University of Maryland, Baltimore2012–2012

Indiana University Health2009–2011

Top Works

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff,Thomas J. Ervin,et al.

20136,565 citations

Melanoma and MAPK Pathways

CAR-T cell therapy research

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja,Deepu Madduri,et al.

20211,578 citations

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook,Georgina V. Long,et al.

2012929 citations

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero,Geoffrey I. Shapiro,et al.

2013693 citations

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Manish R. Patel,John Ellerton,et al.

2017586 citations

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Andrea B. Apolo,Jeffrey R. Infante,et al.

2017581 citations

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

David F. McDermott,Jeffrey A. Sosman,et al.

2016556 citations

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante,Leslie A. Fecher,et al.

2012554 citations

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

Gerald S. Falchook,Karl D. Lewis,et al.

2012539 citations